Boehringer Ingelheim Corporation Release: New Data Presented at AASD Further Demonstrate Benefits of Trajenta® (Linagliptin) With Efficacy and Safety in Specific Patient Populations

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

INGELHEIM, Germany & INDIANAPOLIS, US--(BUSINESS WIRE)--For Non-US and Non-UK Media

Boehringer Ingelheim and Eli Lilly and Company announce new data that reinforce the efficacy and tolerability of linagliptin in people with Type 2 Diabetes (T2D) and liver disease, as well as Asian people with T2D aged 65 years or older. The data add to a growing body of clinical evidence supporting the use of linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor from Boehringer Ingelheim (BI) and Eli Lilly and Company, in a broad range of adults with T2D. The data will be announced on Saturday 9th November during the 2013 International Conference on Diabetes and Metabolism & 5th Asian Association for the Study of Diabetes (AASD) Annual Scientific meeting.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC